Guardant Health shares rose 6.61% over the past week. Headlines during the period covered a new breast cancer role and the company’s liquid biopsy research at the 2026 ESMO Congress. The available information does not show that either development caused the gain.
Investor takeaway: GH.US gained 6.61% over the week, but the reason for the move is unconfirmed.
Weekly move: +6.61%
Advertisement
Guardant Health Inc
GH.US
GH.US
Guardant Health Inc
WealthAwesomeMarket cap
$22.69B
52W high
$191.05
52W low
$68.02
1W change
+6.61%
Beta
1.58
Analyst Price Targets
Based on 26 analysts covering GH · as of Oct 26, 2026
Wall Street analysts forecast GH stock price to rise 1377.2% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
C$201.64
+1377.2% Upside
Previously C$201.71 on Oct 23, 2026
Current Price
C$13.65
Last close
Analyst Breakdown (26 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GH's historical volatility
30-Day Vol
50.2%
Annualized
90-Day Vol
51.5%
Annualized
Trend (90d)
+43.8%
Annualized drift
90d Mean
C$197.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$178.12 | C$149.78 – C$211.83 |
| 60 trading days | C$187.65 | C$146.85 – C$239.77 |
| 90 trading days | C$197.68 | C$146.41 – C$266.90 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
The latest close was US$171.06. Trading volume was 349,604 shares, below the 20-day average of 1,749,984.
Bull case
The weekly gain came alongside company news about a breast cancer role and liquid biopsy research presented at ESMO.
Bear case
The available information does not identify a clear reason for the gain. Trading volume was also below its 20-day average.
What happened: a 6.61% weekly gain
Guardant Health shares rose 6.61% over the week. Recent headlines included an October 20 report about a new breast cancer role and a separate update on the company’s liquid biopsy research at the 2026 ESMO Congress. These developments are worth following, but there’s no confirmation that they drove the share-price increase. The weekly gain is clear; its cause is not. Visit the Guardant Health stock page for more information.
Advertisement
What the numbers show: US$171.06 close, lighter volume
Guardant Health’s latest close was US$171.06. Volume was 349,604 shares, or 0.95 times the 20-day average of 1,749,984. Performance varied across other periods: shares rose 3.77% in one day and 66.19% year to date, but fell 4.10% over one month. The stock closed within its 52-week range of US$68.02 to US$191.05, at 84% of the range. These figures describe recent performance and trading activity, but don’t explain the weekly gain.
What to watch next: further company updates
The breast cancer and liquid biopsy research updates are the main company developments to follow. The available information gives no further event dates or details and does not link either headline to this week’s gain. Guardant Health reported a profit margin of -38.3% and trailing-twelve-month EPS of -3.5. These figures provide financial context, but don’t explain the share-price move. See the GH stock page for more company information.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
